Abstract
The term "malignant lymphoma" describes primary cancers of the lymphoreticular system, almost all of which begin as lymphocytes. This study aimed to assess the impact of therapy type and duration on several hematological and biochemical parameters in lymphoma patients. The study was conducted from July 2023 to October 2023. This study examined one hundred samples in total, fifty sample as control group and fifty sample as patients group. The age range of the participants was between 5 and 77 years old. Some hematological and biochemical tests were analyzed in the current study. The study showed a significant increase (P<0.05) according to type and duration of therapy in patient groups. The study indicated a significant decrease (P<0.05) in red blood cells(RBC), hemoglobin (Hb), lymphocyte and basophils compared with control groups, but indicated a significant increase (P<0.05) in white blood cells (WBC), neutrophils and platelets compared with control groups. Also, the study showed a significant increase (P<0.05) in urea, creatinine, alanine aminotransferase(ALT) and aspartate transaminase (AST) compared with control groups.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.